BRAF V600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma

Auris Nasus Larynx

Volumn 39, Issue 2, 2012, Pages 198-203

  Ahn, Dongbin ^a   Park, June Sik ^a   Sohn, Jin Ho ^a   Kim, Jae Hyug ^a   Park, Sun Kyun ^b   Seo, An Na ^a   Park, Ji Young ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

BRAF mutation; Papillary carcinoma; Prognosis; Thyroid

Indexed keywords

B RAF KINASE; DNA; PARAFFIN; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENDER; GENE MUTATION; HASHIMOTO DISEASE; HUMAN; KOREA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADENOCARCINOMA; AGED; ALLELE; ASIAN; GENETICS; MIDDLE AGED; NECK DISSECTION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; RISK FACTOR; SOUTH KOREA; STATISTICS; THYROID TUMOR; THYROIDECTOMY;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REPUBLIC OF KOREA; RISK FACTORS; STATISTICS AS TOPIC; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856706936     PISSN: 03858146     EISSN: 18791476     Source Type: Journal    
DOI: 10.1016/j.anl.2011.07.011     Document Type: Article

References (17)

1. Tang K.T., Lee C.H. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010, 73:113-128.
2. Ahn H.Y., Park Y.J. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med 2009, 77:537-542.
3. Kim K.H., Kang D.W., Kim S.H., Seong I.O., Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45:818-821.
4. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
5. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
6. Rha S.Y., Lee J.C., Kwon K.H., Lee H.J., Kim K.S., Jo Y.S., et al. The Relationship between the BRAF mutations in thyroid papillary carcinomas and the prognostic factors. J Korean Soc Endocrinol 2005, 20:224-229.
7. Kim T., Roh J.H., Park H.J., Kwon J.E., Kang S.Y., Choi Y.L., et al. The frequency of BRAF mutation in very small papillary thyroid carcinomas. Korean J Pathol 2010, 44:308-314.
8. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12:245-262.
9. Kim E.Y., Kim W.G., Kim W.B., Kim T.Y., Kim J.M., Ryu J.S., et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2009, 71:581-586.
10. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648.
11. Cappelli C., Pirola I., Braga M., De Martino E., Morassi M.L., Gandossi E., et al. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution. Ann Ital Chir 2006, 77:107-113.
12. Ross D.S., Litofsky D., Ain K.B., Bigos T., Brierley J.D., Cooper D.S., et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009, 19:1043-1048.
13. UICC: TNM Classification of Malignant Tumors 2002, Wiley-Liss, New York. sixth ed. L.H. Sobin, C.H. Wittekind (Eds.).
14. Kim T.Y., Kim W.B., Rhee Y.S., Song J.Y., Kim J.M., Gong G., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006, 65:364-368.
15. Kim T.Y., Kim W.B., Song J.Y., Rhee Y.S., Gong G., Cho Y.M., et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005, 63:588-593.
16. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90:6373-6379.
17. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090.